Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), executed a significant sale of 92,238,030 shares on November 24, 2025, at a price of $1,102.35 per share. This transaction totaled approximately $101.68 billion, marking a notable movement in the company's stock.
Following this sale, Lilly Endowment Inc retains the same number of shares in Eli Lilly, which is known for its extensive portfolio in pharmaceuticals, including treatments for cardiometabolic health, oncology, immunology, and neuroscience. The company, headquartered in Indianapolis, Indiana, employs 47,000 full-time staff and has a market capitalization of $1,044.0 billion.
Eli Lilly's financial metrics include a trailing twelve-month price-to-earnings ratio of 56.70 and earnings per share of 20.45, with a dividend yield of 54.3%. Upcoming earnings reports are anticipated on April 29, 2026, with an estimated EPS of $7.53 and revenue of $17.5 billion, followed by another report on August 5, 2026, estimating an EPS of $8.09 and revenue of $18.7 billion.
Insider transactions, such as this one, are reported to the SEC and provide transparency regarding the actions of company executives and board members. While such sales may raise questions, they can stem from various personal or strategic reasons, including diversification or tax planning. Investors are encouraged to analyze patterns of insider activity across multiple insiders and time periods for a more comprehensive view.